Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study to Describe Pain Intensity, Pain Relief and Safety of Neosaldina in the Treatment of Tension-type Headaches (TTH) in Healthy Participants

Completed

Conditions: Healthy Volunteers
Tension-type Headache

First Posted Date: 2018-09-12

Last Posted Date: 2021-06-02

Lead Sponsor: Takeda

Target Recruit Count: 216

Registration Number: NCT03666858

Locations: 🇧🇷
Cemec Centro Multidisciplinar de Estudos Clinicos Ltda-Epp, Sao Bernardo do Campo, SP, Brazil
🇧🇷
Fundacao do ABC, Santo Andre, SP, Brazil
🇧🇷
Sociedade Brasileira e Japonesa de Beneficencia Santa Cruz, Sao Paulo, SP, Brazil

and more 2 locations

A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)

Completed

Conditions: Inflammatory Bowel Diseases
Crohn Disease

First Posted Date: 2018-09-12

Last Posted Date: 2019-10-03

Lead Sponsor: Takeda

Target Recruit Count: 5938

Registration Number: NCT03668249

Locations: 🇪🇸
H. U. de Fuenlabrada, Fuenlabrada, Madrid, Spain
🇪🇸
H.U. Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain
🇪🇸
H.U. Rey Juan Carlos, Mostoles, Madrid, Spain

and more 5 locations

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Phase 2

Completed

Conditions: Dravet Syndrome
Lennox-Gastaut Syndrome
Epilepsy

Interventions: Drug: Placebo
Drug: TAK-935

First Posted Date: 2018-08-28

Last Posted Date: 2021-02-18

Lead Sponsor: Takeda

Target Recruit Count: 141

Registration Number: NCT03650452

Locations: 🇵🇱
Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Wielkopolskie, Poland
🇮🇱
Schneider Childrens Medical Center of Israel, Petach Tikva, Israel
🇺🇸
Rare Disease Research, LLC, Atlanta, Georgia, United States

and more 41 locations

A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System

Phase 1

Terminated

Conditions: Lymphoma
Hematologic Neoplasms
Neoplasms

Interventions: Drug: TAK-981

First Posted Date: 2018-08-27

Last Posted Date: 2024-11-19

Lead Sponsor: Takeda

Target Recruit Count: 109

Registration Number: NCT03648372

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 5 locations

A Study of Soticlestat in Adults and Children With Rare Epilepsies

Phase 2

Active, not recruiting

Conditions: Dravet Syndrome (DS)
Lennox-Gastaut Syndrome (LGS)
Epilepsy

Interventions: Drug: Soticlestat

First Posted Date: 2018-08-17

Last Posted Date: 2024-02-21

Lead Sponsor: Takeda

Target Recruit Count: 156

Registration Number: NCT03635073

Locations: 🇺🇸
Center for Rare Neurological Diseases, Norcross, Georgia, United States
🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇮🇱
Tel Aviv Sourasky Medical Center PPDS, Tel Aviv, Israel

and more 45 locations

Agrylin Drug Use-Result Survey

Completed

Conditions: Essential Thrombocythemia (ET)

First Posted Date: 2018-08-10

Last Posted Date: 2023-02-27

Lead Sponsor: Takeda

Target Recruit Count: 1826

Registration Number: NCT03625895

Locations: 🇯🇵
Nerima-ku, Nerima-ku, Tokyo, Japan
🇯🇵
Bunkyo-ku, Bunkyo-ku, Tokyo, Japan
🇯🇵
Koganei-city, Koganei-city, Tokyo, Japan

and more 295 locations

Survey Study for Velaglucerase Alfa (VPRIV) in Japan

Completed

Conditions: Gaucher Disease

First Posted Date: 2018-08-10

Last Posted Date: 2025-01-10

Lead Sponsor: Takeda

Target Recruit Count: 63

Registration Number: NCT03625882

Locations: 🇯🇵
Nagoya, Nagoya, Aichi, Japan
🇯🇵
Higashihiroshima, Higashihiroshima, Hiroshima, Japan
🇯🇵
Fukuyama, Fukuyama, Hiroshima, Japan

and more 28 locations

A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Thalidomide
Drug: Dexamethasone

First Posted Date: 2018-08-01

Last Posted Date: 2020-01-14

Lead Sponsor: Takeda

Registration Number: NCT03608501

Locations: 🇧🇷
Instituto COI de Educacao e Pesquisa, Rio de Janeiro, RJ, Brazil
🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
🇧🇷
Universidade Estadual de Campinas UNICAMP - HEMOCENTRO, Campinas, SP, Brazil

and more 3 locations

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: ALK+ Advanced NSCLC

Interventions: Drug: Brigatinib
Drug: Alectinib

First Posted Date: 2018-07-24

Last Posted Date: 2024-08-21

Lead Sponsor: Takeda

Target Recruit Count: 248

Registration Number: NCT03596866

Locations: 🇦🇷
Sanatorio Duarte Quiros, Cordoba, Argentina
🇨🇳
Peking Union Medical College Hospital - East, Beijing, Beijing, China
🇨🇱
Centro de Investigacion Clinica Bradford Hill, Recoleta, Santiago, Chile

and more 108 locations

An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004

Phase 3

Completed

Conditions: Short Bowel Syndrome

Interventions: Drug: Teduglutide
Device: Syringe
Device: Needle
Device: Vial Adapter for Device

First Posted Date: 2018-07-23

Last Posted Date: 2023-03-15

Lead Sponsor: Takeda

Target Recruit Count: 11

Registration Number: NCT03596164

Locations: 🇯🇵
Tohoku University Hospital, Miyagi-Ken, Japan
🇯🇵
Osaka University Hospital, Osaka, Japan
🇯🇵
Hyogo College of Medicine Hospital, Hyogo, Japan

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy